Laser pulses
Colin Kerr
Published: Saturday, September 1, 2018
OD-OS has announced that it has achieved the revocation of the MicroPulse™ Patent (Patent no EP1856774) by Iridex Cooperation in oral proceedings at the European Patent office.
Winfried Teiwes, Managing Director, OD-OS GmbH said: “We fully respect the effort Iridex Cooperation has put into the clinical development how tissue-sparing, shorter laser pulses can be effective for retinal treatments. With Navilas®, we are providing a contact-free, easy-to-use and transparent delivery technique of these laser pulses, which allows standardised treatment protocols. We will work with Navilas® users to make microsecond pulse treatment a non-contact, non-damaging but long-lasting treatment in clinical practice, and a viable addition to often chronical injections.”
www.od-os.com
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular
Long-awaited cellular therapies for corneal endothelial disease enter the clinic.
Balancing Innovation and Safety
Ensuring access to advanced cell therapies amid regulatory overhaul.
With Eyes on Its Future, ESCRS Celebrates Its Past
Winter Meeting offers opportunities to experiment with new concepts and formats.
Best of ESCRS Winter Meeting 2024
Following the New Generation
EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.
Refocus on Multifocals
Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.
Common Myths in Presbyopia Correction
Patient education key to satisfaction with refractive IOLs.
Reversible Multifocality
Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.
Managing a Cataract Surgery Refractive Miss
Weighing the pros and cons of options for intraocular intervention.
Unleashing OCT’s Full Potential
Performance of newest tool for corneal evaluation meets or beats older standard technologies.